Alkem Laboratories Limited reported its Q3 FY25 financial results, highlighting modest growth in revenue and profitability, supported by operational efficiencies.
Key Highlights – Q3 FY25 (YoY Comparison)
- Revenue from Operations: ₹3,374.28 crore, up 1.5% YoY from ₹3,323.87 crore
- Total Income: ₹3,467.27 crore, up 1% YoY from ₹3,417.51 crore
- Profit Before Tax (PBT): ₹731.07 crore, up 12% YoY from ₹654.90 crore
- Net Profit (PAT): ₹640.79 crore, up 6% YoY from ₹604.28 crore
Alkem Laboratories Limited posted strong financial results for Q3 FY25, with key highlights showing growth in operational profitability and margins:
- EBITDA: ₹760 crore, up from ₹708 crore YoY, exceeding the estimate of ₹712 crore.
- EBITDA Margin: 22.51%, higher than 21.29% YoY and beating the estimated 20.5%.
The company’s operational performance was supported by effective cost management and higher revenue contributions. The improved margins signal enhanced efficiency, despite rising material costs during the quarter.
Alkem Laboratories Limited has declared an interim dividend of ₹37 per equity share on a face value of ₹2 per share for the financial year 2024-2025. The payment of the dividend will commence on and from February 28, 2025. The record date for determining eligibility is set for February 14, 2025, as per the company’s regulatory filings.
Nine-Month Performance
- Revenue: ₹9,820.77 crore, up 1% YoY
- Net Profit: ₹1,892.99 crore, up 26% YoY
Key Drivers
Revenue growth was driven by steady demand in key markets, while profitability improved due to efficient cost management, particularly in raw material consumption and other operational expenses.
Alkem Laboratories aims to continue this positive trend by capitalizing on its robust portfolio and international presence.
